<SEC-DOCUMENT>0001178913-24-001778.txt : 20240520
<SEC-HEADER>0001178913-24-001778.hdr.sgml : 20240520
<ACCEPTANCE-DATETIME>20240520071509
ACCESSION NUMBER:		0001178913-24-001778
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240520
FILED AS OF DATE:		20240520
DATE AS OF CHANGE:		20240520

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sol-Gel Technologies Ltd.
		CENTRAL INDEX KEY:			0001684693
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38367
		FILM NUMBER:		24962344

	BUSINESS ADDRESS:	
		STREET 1:		7 GOLDA MEIR ST.
		STREET 2:		WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			7403648
		BUSINESS PHONE:		97289313433

	MAIL ADDRESS:	
		STREET 1:		7 GOLDA MEIR ST.
		STREET 2:		WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			7403648
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2431489.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"><br>
        <font style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;">UNITED STATES</font></div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;">
      <div style="text-align: center; line-height: 1.25;">FORM&#160;6-K</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Report of Foreign Private Issuer</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Pursuant to Rule&#160;13a-16&#160;or&#160;15d-16</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Under the Securities Exchange Act of 1934</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">For the month of May 2024</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Commission File Number 001-38367</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SOL-GEL TECHNOLOGIES LTD.</div>
      <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">7 Golda Meir Street</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Ness Ziona 7403650, Israel</div>
      <div style="text-align: center; line-height: 1.25;">(Address of principal executive offices)</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 24.5pt; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F&#160;or Form&#160;40-F.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;">Form&#160;20-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form&#160;40-F&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 24.5pt; line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form&#160;6-K&#160;in paper as permitted by Regulation&#160;S-T&#160;Rule 101(b)(1):&#160;&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 24.5pt; line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form&#160;6-K&#160;in paper as permitted by Regulation&#160;S-T&#160;Rule 101(b)(7):&#160;&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;"><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">On April 1, 2024, Sol-Gel Technologies Ltd. (the &#8220;Company&#8221;) issued a press release entitled &#8220;Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates&#8221;.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Attached hereto is the following exhibit:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><a href="exhibit_99-1.htm">Exhibit 99.1</a>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<a href="exhibit_99-1.htm">Press release dated May 20, 2024</a></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Exhibit 99.1 (other than the two paragraphs immediately preceding the heading &#8220;Financial Results for the Financial Results for the First Quarter Year Ended March 31<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup>, 2024&#8221;) is hereby incorporated by
      reference into the Company's Registration Statements on Form S-8 (Registration Nos. 333-223915 and 333-270477) and its Registration Statement on Form F-3 (Registration No. 333-264190).</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; text-align: center;">2<br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURES</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="zae6ae14f89494e42ba1ea8da24e94b43" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: top;" colspan="2">
            <div style="line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: middle; width: 4%;"><br>
          </td>
          <td style="vertical-align: middle; width: 46%;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Date:&#160; May 20, 2024</div>
          </td>
          <td style="vertical-align: top; width: 4%;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 46%;">
            <div style="line-height: 1.25;">/s/ Gilad Mamlok</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: top; width: 4%;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: top; width: 46%;">
            <div style="line-height: 1.25;">Gilad Mamlok</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: top; width: 4%;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: top; width: 46%;">
            <div style="line-height: 1.25;">Chief Financial Officer</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">
        <div style="text-align: center;">&#160;3</div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;">
        <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br>
          <br>
        </div>
        <img width="309" height="51" src="image00001.jpg"></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Sol-Gel Reports First Quarter 2024 Financial Results and Provides </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Corporate Updates</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="zbd159d026e3240a3a5e02c234c7bca79" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="z6f00abd6422743249631fc67c12ae8ab" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO&#174; in China, Hong Kong, Macau, Taiwan and Israel, for a total consideration of up to $<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup>15 million.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="z0c5d21b4f74d4024b5fcd0792c9484be" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Sol-Gel<font style="font-weight: bold;">&#160;</font>recently initiated a proof-of-concept study for SGT-210 (topical erlotinib) in patients with Darier disease.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="z3a58645b9fbc404d8ef637b1c40d5f3f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Highly encouraging clinical response for SGT-210 from a Compassionate use treatment for a pediatric patient suffering from an ultra-rare disease.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="zf9338b9891df48358231327f8266e2bf" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Sol-Gel's collaboration partner, Padagis, submitted First-to-File ANDA Drug Product Generic to Zoryve&#174; Cream.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="z93dd7e05be8941dba17b6817a759b84b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Sol-Gel maintains its cash runway into the second half of 2025.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">NESS ZIONA, Israel, May 20, 2024 (GLOBE NEWSWIRE) - <font style="font-weight: bold;">Sol-Gel Technologies, Ltd.</font>&#160;(NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with
      severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and EPSOLAY<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, today announced financial results
      for the first quarter ended March 31, 2024 and provided a corporate update.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><u>Q1 2024 and Recent Corporate Developments</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zf7505db8188141bb926678f325c19abe" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>On May 16, Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement, pursuant to which Beimei purchases and licenses the rights to commercialize and manufacture TWYNEO&#174; in China, Hong Kong, Macau, Taiwan and Israel. Sol-Gel is
              expected to receive, subject to applicable government approvals, a total consideration of up to $15 million, out of which $10 million will be paid as upfront and regulatory milestones, and the remaining $5 million will be paid as royalties on
              net sales.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25"><br>
      <hr noshade="noshade" align="left" style="background-color: #000000; border: 0px; height: 1px; width: 2in; margin-left: 0pt; margin-right: auto; color: #000000;">
      <div style="line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> All $ amounts are in U.S. dollars</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%--> </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z77ffc1a5c21f4f5db9a753eb0713ea81" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>We initiated a proof-of-concept study for SGT-210 (topical erlotinib) in patients with Darier disease, and have been using SGT-210 in a compassionate use treatment for to a pediatric patient suffering from an ultra-rare disease.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z86beba6f101f4d3a902458138553ab1a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>On April 1, 2024, Sol-Gel announced that Padagis Israeli Pharmaceuticals, Sol-Gel's collaboration partner, submitted a first-to-file Abbreviated New Drug Application (ANDA) to the for Roflumilast Cream 0.3%, a drug product generic to
              Zoryve<font style="font-weight: bold;">&#174;</font> Cream (roflumilast cream 0.3%) indicated for the treatment of plaque psoriasis in patients six years of age and older. On March 26, 2024, Arcutis Biotherapeutics Inc (Nasdaq: ARQT) initiated a
              patent infringement action in the US District Court in New Jersey regarding the Padagis Roflumilast 0.3% ANDA. Should the ANDA is approved by the FDA, Padagis believes that its product may be entitled to 180 days of generic market
              exclusively. According to IQVIA, the annual market sales in the 12 months ended in January 2024 for Zoryve<font style="font-weight: bold;">&#174; </font>Cream were approximately $ 95 million<font style="font-weight: bold;">.</font></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="z2e7f2e1ebd334a0694dc87817243dcf6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 17.85pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>SGT-610 Phase 3 clinical trial is ongoing. On November 30, 2023, Sol-Gel announced that it had begun for Gorlin syndrome,<font style="font-style: italic;">&#160;</font>with the first patient screened. Sol-Gel acquired topically applied
                patidegib, a hedgehog signaling pathway blocker 2% from PellePharm Inc. and is currently the only therapy in development to prevent the development of new BCC lesions in Gorlin syndrome patients. SGT-610 is a new topical hedgehog inhibitor
                to prevent the new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome that is expected to have an improved safety profile compared to oral hedgehog inhibitors. Sol-Gel is conducting a Phase 3 clinical trial to investigate
                SGT-610 in approximately 140 subjects at about 40 experienced clinical centers in North America, the United Kingdom, and Europe.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" id="zf30d46ee58bd446cb0eb6041ae746705" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Total prescriptions for TWYNEO in Q1 2024 totaled approximately 21,000, declining 23% from Q4 2023.&#160; Patient refills in Q1 declined by 18% for the same time period.&#160; This is in part due to a targeted patient adherence campaign facilitated
              in Q4 2023 and to the adjustments in the&#160;promotional model.&#160; TWYNEO new prescribers continue to grow with a 5% quarterly increase.&#160; Average weekly TWYNEO prescriptions/prescriber remained relatively constant at 1.6/week for Q1 with commercial
              managed care coverage for TWYNEO increasing by 1.5M lives since Q4 2023 to 102.2M commercial lives covered.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zd8ae99551bd0493096412c4a1458430d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Total prescriptions for EPSOLAY in Q1 2024 totaled approximately 12,500, declining 14% from Q4 2023. &#160;Patient refills declined by 8% for Q1 2024 vs. Q4 2023.&#160; Consistent with TWYNEO, the quarterly decrease for EPSOLAY was negatively
              impacted by strong prescriptions in Q4 2023 influenced by a targeted patient adherence campaign and to the adjustments in the&#160;promotional model.&#160;&#160; EPSOLAY new prescribers continue to grow with a 6% increase vs. Q4 2023.&#160; Average weekly
              EPSOLAY prescriptions/prescriber remained consistent at 1.3/week for Q1.&#160; Managed care coverage for EPSOLAY has grown since Q4 2023 with total commercial lives covered increasing by over 1M lives to 67.1M commercial lives covered.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <div style="line-height: 1.25;"><font style="font-weight: bold;">Alon Seri-Levy, Ph.D., Chief Executive Officer of Sol-Gel, stated: </font>"We continue to focus on rare indications affecting the skin which have no approved treatments.&#160; In this regard,
      we are continuing to enroll patients for our pivotal Phase 3 clinical trial of SGT-610 for the prevention of new basal cell carcinomas in patients with Gorlin Syndrome, with a potential market estimated at more than $300 million. We also initiated a
      proof-of-concept study for SGT-210 (topical erlotinib) in patients with Darier disease, with results expected in H1/2025.&#160; In addition, SGT-210 is currently being used in a Compassionate use treatment of a pediatric patient suffering from an
      ultra-rare disease, and given the preliminary highly encouraging<u>&#160;</u>response, the treatment with SGT-210 continues, and the company will explore other commercially viable keratoderma indications&#8221; said Alon Seri-Levy, Ph.D., Chief Executive
      Officer of Sol-Gel.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">"We recently signed an agreement with Beimei Pharma for the commercialization of TWYNEO in China, Hong Kong, Macau, Taiwan and Israel. This agreement demonstrates the potential of TWYNEO, and we
      expect to announce other agreements regarding the commercialization of both our FDA-approved assets, TWYNEO and EPSOLAY, in other territories,&#8221; further added&#160;Dr.&#160;Seri-Levy.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Financial Results for the First Quarter Year Ended March 31<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup>, 2024</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">Total revenue in the first quarter was&#160;$0.5 million, which primarily consisted of licensing revenue from Galderma and Searchlight, compared to $0.3 million revenues for the same period in 2023. As
        disclosed in connection with the filing of the June 30, 2023, financial statements, in the first quarter of 2023, wholesaler ordering patterns were disrupted ahead of Galderma's implementation of a new enterprise resource planning system, which
        impacted its standard forecasting procedures and its quarterly assessment of rebate accruals. As a result, previously reported revenue for the first quarter of 2023 was revised as reflected in the below income statement.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Research and development expenses were&#160;$5.3 million&#160;compared to&#160;$9.4 million&#160;for the same period in 2023. The decrease of&#160;$4.1 million&#160;was primarily attributed to a decrease of&#160;$1.8 million&#160;in
        R&amp;D expenses related to SGT-610 and SGT-210, a decrease of $1.4 million in expenses related to clinical development of a generic product candidate, a decrease of $0.3 million in payroll expenses, and a decrease of $0.3 in general R&amp;D
        expenses.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">General and administrative expenses were&#160;$1.8 million compared to&#160;$2.0 million&#160;for the same period in 2023. The decrease of&#160;$0.2 million&#160;was mainly attributed to a decrease in professional
        expenses.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Sol-Gel&#160;reported a net loss of&#160;$6.3 million&#160;for the first quarter of 2024 and a loss of&#160;$0.23&#160;per basic and diluted share, compared to a net loss of&#160;$10.7 million&#160;and a loss of&#160;$0.43&#160;per basic and
        diluted share for the same period in 2023.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">As of&#160;March 31, 2024,&#160;Sol-Gel&#160;had&#160;$16.2 million&#160;in cash, cash equivalents, and deposits and&#160;US$16.8 million&#160;in marketable securities for a total balance of&#160;$33.0 million. The Company expects its
        cash resources to fund operational and capital expenditure requirements into the second half of 2025.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Gorlin Syndrome and SGT-610</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">SGT-610, a hedgehog signaling pathway blocker, has the potential to be the first ever treatment for prevention of BCCs in Gorlin syndrome patients, if approved. Gorlin syndrome, an autosomal dominant
      genetic disorder affecting approximately 1 in 27,000-31,000 people in the&#160;U.S., is mostly caused by inheritance of one defective copy of the tumor suppressor patched homolog 1 (PTCH1) gene. Normally, the PTCH1 gene blocks the smoothened, frizzle
      class receptor (SMO) gene, turning off the hedgehog signaling pathway when it is not needed. Mutations in the PTCH1 gene may cause a loss of PTCH1 function, release of SMO, and may allow BCC tumor cells to divide uncontrollably. Patidegib, the active
      substance in SGT-610, is designed to block the SMO signal, thus, allowing cells to function normally and reducing the production of new tumors.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Sol-Gel Technologies</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Sol-Gel Technologies, Ltd.&#160;is a dermatology company focused on identifying, developing, and commercializing or partnering drug products to treat skin diseases.&#160;Sol-Gel&#160;developed TWYNEO, which is
        approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older, and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults. both drugs are
        exclusively licensed to and commercialized by Galderma in the US; and are exclusively licensed to Searchlight in Canada.&#160; TWYNEO was purchased and licensed by Beimei Pharma to be exclusively commercialized by them in China, Hong Kong, Macau, Taiwan
        and Israel.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">The Company&#8217;s pipeline also includes a Phase 3 clinical trial of Orphan and Breakthrough Drug candidate SGT-610, which is a new topical hedgehog inhibitor being developed to prevent the new basal
        cell carcinoma lesions in patients with Gorlin syndrome that is expected to have an improved safety profile compared to oral hedgehog inhibitors as well as topical drug candidate SGT-210 under investigation for the treatment of&#160;rare
        hyper-keratinization disorders.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">For additional information, please visit our new website: &#160;<u>www.sol-gel.com</u></div>
      <br>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Forward-Looking Statements</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate
      to matters of historical fact should be considered forward-looking statements, including, but not limited to the amounts to be received under the agreement with Beimei, out-licensing Epsolay and Twyneo in additional territories, the potential of
      Sol-Gel&#8217;s assets including Twyneo, Epsolay SGT-610, and SGT-210, and SGT-610&#8217;s market value.&#160; In some cases, you can identify forward-looking statements by terminology such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221;
      &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; or the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our management&#8217;s current expectations and
      are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are
      not limited to, a delay in the timing of our clinical trials, the success of our clinical trials, and an increase in our anticipated costs and expenses, as well as the following factors: (i) the adequacy of our financial and other resources,
      particularly in light of our history of recurring losses and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; (ii) our ability to complete the development of our product candidates; (iii) our ability
      to find suitable co-development partners; (iv) our ability to obtain and maintain regulatory approvals for our product candidates in our target markets, the potential delay in receiving such regulatory approvals and the possibility of adverse
      regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; (v) our collaborators&#8217; ability to commercialize our pharmaceutical product candidates; (vi) our ability to obtain and maintain adequate protection
      of our intellectual property; (vii) our collaborators&#8217; ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; (viii) our collaborators&#8217; ability to establish adequate sales, marketing
      and distribution channels; (ix) acceptance of our product candidates by healthcare professionals and patients; (x) the possibility that we may face third-party claims of intellectual property infringement; (xi) the timing and results of clinical
      trials that we may conduct or that our competitors and others may conduct relating to our or their products; (xii) intense competition in our industry, with competitors having substantially greater financial, technological, research and development,
      regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; (xiii) potential product liability claims; (xiv) potential adverse federal, state and local government regulation in&#160;the United
      States,&#160;China, Europe&#160;or&#160;Israel; and (xv) loss or retirement of key executives and research scientists; (xvi) general market, political and economic conditions in the countries in which the Company operates; and,&#160; (xvii) the current war between
      Israel and Hamas and any deterioration of the war in Israel into a broader regional conflict involving&#160;Israel&#160;with other parties. These factors and other important factors discussed in the Company's Annual Report on Form 20-F filed with
      the&#160;Securities and Exchange Commission&#160;(&#8220;SEC&#8221;) on March 13, 2024, and our other reports filed with the&#160;SEC,&#160;could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Except as
      required by law, we undertake no obligation to update any forward-looking statements in this press release.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Sol-Gel Contact :</div>
    <div style="line-height: 1.25;">Gilad Mamlok</div>
    <div style="line-height: 1.25;">Chief Financial Officer</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><u>info@sol-gel.com</u></div>
    </div>
    <div style="line-height: 1.25;">+972-8-9313433</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><img width="198" height="40" src="image00001.jpg"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Source: Sol-Gel Technologies Ltd.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">4</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</div>
    <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share data)</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">(Unaudited)</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z88c97bb1260a4be2b7690665e7347aeb" class="cfttable">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 1pt;">Three months ended</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 1pt;">March 31</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 1pt;"> 2023</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 1pt;">2024</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -14.2pt; margin-left: 15.9pt; line-height: 1.25; font-weight: bold;">LICENSE REVENUES</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">300</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">466</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-indent: -14.2pt; margin-left: 15.9pt; line-height: 1.25; font-weight: bold;">RESEARCH AND DEVELOPMENT EXPENSES</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">9,386</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">5,345</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -14.2pt; margin-left: 15.9pt; line-height: 1.25; font-weight: bold;">GENERAL AND ADMINISTRATIVE EXPENSES</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">1,977</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">1,833</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-align: justify; text-indent: -14.2pt; margin-left: 15.9pt; line-height: 1.25; font-weight: bold;">OPERATING LOSS</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">11,063</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">6,712</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -14.2pt; margin-left: 15.9pt; line-height: 1.25;"><font style="font-weight: bold;">FINANCIAL INCOME, </font>net</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">(342</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">)</div>
            </div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">(368</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">)</div>
            </div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
            <div style="text-align: justify; text-indent: -14.2pt; margin-left: 15.9pt; line-height: 1.25; font-weight: bold;">LOSS FOR THE PERIOD</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">$</div>
            </div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">10,721</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">$</div>
            </div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">6,344</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -14.2pt; margin-left: 15.9pt; line-height: 1.25; font-weight: bold;">BASIC AND DILUTED LOSS PER ORDINARY SHARE</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">0.43</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">0.23</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
            <div style="text-indent: -14.2pt; margin-left: 15.9pt; line-height: 1.25; font-weight: bold;">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN </div>
            <div style="text-indent: -14.2pt; margin-left: 15.9pt; line-height: 1.25; font-weight: bold;">&#160;&#160;&#160; COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">24,944,220</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">27,857,620</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font></div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">5</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25;">CONDENSED CONSOLIDATED BALANCE SHEETS</div>
    <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share data)</div>
    <div style="text-align: center; line-height: 1.25;">(Unaudited)</div>
    <div style="text-align: center; line-height: 1.25;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="zfaa43d60085d47d0a369fba9422b0e02" class="cfttable">

        <tr>
          <td valign="bottom" style="vertical-align: top;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top;" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">December 31,</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top;" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">March 31,</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2023</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2024</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Assets</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom;">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">CURRENT ASSETS:</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; margin-left: 9pt;">Cash and cash equivalents</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">7,513</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">11,210</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-align: justify; line-height: 1.25; margin-left: 9pt;">Bank deposits</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">10,012</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">5,012</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; margin-left: 9pt;">Marketable securities</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">20,471</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">16,795</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-align: justify; line-height: 1.25; margin-left: 9pt;">Accounts receivables</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">377</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">869</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; margin-left: 9pt;">Prepaid expenses and other current assets</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">2,794</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">2,121</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">TOTAL CURRENT ASSETS</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">41,167</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">36,007</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">NON-CURRENT ASSETS:</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; margin-left: 9pt;">Restricted long-term deposits and cash equivalents</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">1,284</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">1,264</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-align: justify; line-height: 1.25; margin-left: 9pt;">Property and equipment, net</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">434</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">366</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; margin-left: 9pt;">Operating lease right-of-use assets</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">1,721</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">1,612</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-align: justify; line-height: 1.25; margin-left: 9pt;">Other long-term assets</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">55</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">45</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; margin-left: 9pt;">Funds in respect of employee rights upon retirement</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">626</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">617</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">TOTAL NON-CURRENT ASSETS</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">4,120</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">3,904</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">TOTAL ASSETS</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">45,287</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">39,911</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Liabilities and shareholders' equity</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">CURRENT LIABILITIES:</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-align: justify; line-height: 1.25; margin-left: 9pt;">Accounts payable</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">154</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">582</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; margin-left: 9pt;">Other accounts payable</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">3,921</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">4,257</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; line-height: 1.25; margin-left: 9pt;">Current maturities of operating leases</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">447</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">386</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">TOTAL CURRENT LIABILITIES</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">4,522</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">5,225</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">LONG-TERM LIABILITIES:</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;Operating leases liabilities</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">1,206</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">1,133</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; margin-left: 9pt;">Liability for employee rights upon retirement</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">915</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">902</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">TOTAL LONG-TERM LIABILITIES</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">2,121</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">2,035</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">TOTAL LIABILITIES</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">6,643</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">7,260</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">SHAREHOLDERS' EQUITY:</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-align: justify; line-height: 1.25;">Ordinary shares, NIS 0.1 par value &#8211; authorized: 50,000,000 as of December 31, 2023 and March 31, 2024, </div>
            <div style="text-align: justify; line-height: 1.25;">&#160;&#160; respectively; issued and outstanding: 27,857,620 and 27,857,620 as of December 31, 2023 and March 31, </div>
            <div style="text-align: justify; line-height: 1.25;">&#160;&#160; 2024, respectively</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">774</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">774</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25;">Additional paid-in capital</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">258,173</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">258,524</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; line-height: 1.25;">Accumulated deficit</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">(220,303</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">(226,647</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">TOTAL SHAREHOLDERS' EQUITY</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">38,644</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">32,651</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">45,287</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">39,911</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; text-align: center;"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">6</font></div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div class="BRPFPageFooter">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !@ =8# 2(  A$! Q$!_\0
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MJ&H:9I?B31/",-[=.#-/_9'AG2[19&(M;2VA"1( 26W_  6V_P""9=S,D/\
MPT?+;F1T17N?@_\ '2*'<YVC?*/AHZ1(#C?)*4C0'<[J@9E^JOA9^W7^QO\
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MJ%GK6A:[I,MW;7EK%J_A_7M-TW6M+DN;2ZMEOK"#[1;7$'F0O_&#\/O^"_\
M_P %!O!D<B>)-5^$/Q:+QK&LWC_X:0Z9+"RMEIXO^%6:Q\-8?.<?*1-#-
M5@#9)_9']E+_ (.#/V>_B[KNF^"_VA?!.H_LZZ[JEQ:6&G^,_P"W%\9_"V>\
MG:.WW:]K*Z7HFN>"(KB[EC$5QJ&CZSX<TVT%Q>>(/%FE6ML9Y #^@NC-06US
M;WMM;WEG<07=I=P17-K=6TJ3VUS;3QK+!<6\\3/%-!-$ZR12QLT<D;*Z,5()
M_&G_ (+D_M8Z[^S;^Q^_A#P-JCZ3\0OVAM>G^&ECJ-K<O:ZIHG@2+2Y]2^(^
MN:6_V.YB>YGT\Z3X);$]A?6,7CAM;TN\BU#28#0!\/\ _!2#_@N]-X(UWQ'\
M#_V))]&U37=%OI]&\5?M!W]K8^(=!LK^S,\.HZ?\*=%NTNM%\0R6EZL5NWCK
M7X=4\,W2V^HQ>'_#VMV5WI'BZ+Y/_8O_ ."3/[1'_!1%=._:A_;3^,/Q,T3X
M?>+HHKWPQ=:YJMQXE^,GQ*\.,C?8]6T2\\7-J^G^ ?!$P='\*7VIZ1K U;3+
M=+G0_"</A:_T'Q!>_F/_ ,$U?V<M(_:H_;6^!WPC\46_VKP1<^(+SQ=X]MFA
M>:WU#PAX"TB_\7ZIH%Z(KNRN(;/Q?)H]KX-GO+6<7-@/$(OH5=[<*?\ 1@@A
MAMH8;:VABM[>WBC@@@@C6*&"&)!'%##%&%2.*-%5(XT541%"J  !0!^9?@+_
M ((Y?\$Y? %E:V]K^SAHGBF]@MX8KG5_'OB;QKXQO=2FCMQ!)>W5GJ_B*;0;
M>XN?FGFBTG1M-L$N',EM9VX6-4Q_B1_P1:_X)S?$;3=3M5^ R> -6OK6\@M/
M$WPW\8^,?#6I:)/=J0+_ $S1YM:U+P5-=6DFV:SAUKPGJ^G1,@C:PDMFE@D_
M5&B@#^(']O3_ ()#?'7]@>=_VB/V=_'GBKQS\(_"E['J_P#PF&AW-SX9^,7P
M<F%])'9:AKLOAN2S74-*M(I+ ?\ "P/"K:2T%[)>MJ_A;PQIUK::AJ7OG_!.
M_P#X+P^/? VJ^'?A%^VIJ%W\0?A_=3Z5HFD?'$0++X_\$1%8M.CN/B ENJGX
M@>';<+;76I>(/*_X6!:*-6U2_N?'=Y=6MA:?U[:CIVGZOI]]I.K6-GJFE:I9
MW6G:GIFHVL-[I^HZ?>P/;7EC?6=RDMM=V=W;2R6]U:W$<D$\$CQ2H\;LI_SE
M_P#@HQ^S7IG[)G[9/QK^"WAJUO+;P/I&O67B/X>+=1:KY<?@;QMHVG^+=!TJ
MRU'6)[R^UV#PG'J\W@JYUV:^O9=1U3PUJ,EU<&^6ZCC /]&;2]4TS7-,T[6M
M%U&QU?1M7L;35-)U;2[NWU#3-4TS4+>.[L-1TZ_M))K6]L;VUFBN;2[MI9;>
MYMY8YH9'C=6-UE5U9'4,C JRL RLK##*RG((()!!&".#7X"?\&]W[2_B#XN?
MLQ>.O@CXMU/4=:U;]F_Q/H=CX<O[_=-]E^&/Q#M-7OO"/AX7\KR7-XV@:_X7
M\<6ME',YCTGPW)X<T.Q2'3=-LX(OW\H _P \?_@K3\,O _P@_P""AO[2/@3X
M<>'M/\*>$+/6_!&OZ?X>TFWBL]*TN\\<?"WP-XZUZ#2[&W2*UT[36\0^)-5F
ML-,LXH;+3;26&QLH8;6WAC7^I_\ X(0_"GP'X+_X)]?#;XB>'_#VGV?C7XQ:
MY\1==\?^)!;0MK&N3>%/B=XU\!^';"?43']L.CZ-H7ANV.FZ29C866H:AK>H
MVT$5YK.HRW'\SG_!;3_E)U^TS_W1G_UGWX45_51_P1+_ .48O[,W_=9O_6@O
MBO0!^JE%%% !1110 4444 %13SPVT,UQ<2QP6]O%)///,ZQQ0PQ(9)999'(5
M(XT5G=V(55!8D $U+7PY_P %+_%MWX*_8#_:VUJRB$L]S\$O&7A?&2#'#XYL
M?^$)N;E&!!62TMO$,UU$P.5DA4CD4 ?Q,_\ !2G]M_Q)^W'^TCXE\<+J6J1_
M"+PA=ZCX4^"/A2YFN([+2?!=K=^6?$TNE/';Q6GBCQ_+:P^(_$LLT,VI6R/I
M'A:?4M0TOPIHK0_T,?\ !!G]@#PY\.OA5IG[9WQ*\/VU_P#%;XH6VHI\(EU2
M"2:3X??#&1YM+DU_3K2ZMHHK#Q3\13%?3#6[<WMQ'\/)=)M-'U&PM?%OB_3K
M_P#C@K_43^%7@G0_AI\+_AO\./#$#VOAKX?^ O!_@GP];23RW4EOH?A7P]IV
MA:3!)<SLT]P\-A86\;3S,TLK*9)&+L30!WM%%% !1110!\P_MB_LM^!_VQOV
M?/'WP)\;Q6=N/$>FR7?@_P 47&G#4KKP%X_TZ"X?PGXVTV!+FPNGGT:_E,>I
M65GJ6F2:]X=O-;\,W-]%INMWP?Z;BCCACCAAC2*&)$BBBB18XXXXU"I'&B@*
MB(H"HB@*J@   4^B@ K^+/\ X.)OAGX.\'?M:?#3QIX9T33M$U;XF?""+4O&
MATRRM;)->\0:#XKU[2XO$FI?9XHWO-;N]'DTW2;R^N&DEFLM$TQ&.Z%F?^TR
MOX\?^#DS_DX7]G?_ +(SK/\ ZF^IT >1?\$2/V$?V</VV/\ AIK_ (:"\+:U
MXE_X5G_PIC_A$?[(\6>(/"_V+_A,_P#A:_\ ;WVC^PKVS^W?:?\ A%-%\K[5
MYGV;R)?(V?:)MW[R?\.(_P#@G!_T2WQG_P"'8^('_P NZ_-[_@V7_P";V/\
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MM?AOXSTR75/"_A_[5--+=W']@:WI'C&UL%FV6^F^'9- T/3DCLM*BAB^5_\
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MBBBO7)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
